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The growth and metastasising capacity of solid tumours are dependent on angiogenesis. Vascular endothelial growth factor is a
mediator of angiogenesis. In this study we investigated whether vascular endothelial growth factor is associated with the
natural course of the disease in primary invasive breast cancer. In 574 tumours of patients with node-negative invasive breast
cancer the cytosolic levels of vascular endothelial growth factor were measured using a quantitative enzyme-linked
immunosorbent assay. These patients did not receive adjuvant systemic therapy and were followed for a median follow-up
time of 61 months (range 2–155 months) after the primary diagnosis. Correlations with well-known prognostic factors, and
univariate and multivariate survival analyses were performed. Vascular endothelial growth factor level was positively associated
with age and tumour size (P=0.042 and P=0.029, respectively). In addition, vascular endothelial growth factor level was
inversely, but weakly correlated with progesterone receptor levels (PgR) (rs=70.090, P=0.035). A high vascular endothelial
growth factor level (equal or above the median level of 0.53 ng mg
71 protein) predicted a reduced relapse-free survival and
overall survival in the univariate survival rate analysis (for both P=0.005). In the multivariate analysis as well, vascular endothelial
growth factor showed to be an independent predictor of poor relapse-free survival and overall survival (P=0.045 and
P=0.029, respectively), in addition to age, tumour size and PgR. The results show that cytosolic levels of vascular endothelial
growth factor in tumour tissue samples are independently indicative of prognosis for patients with node-negative breast cancer
who were not treated with adjuvant systemic therapy. This implies that vascular endothelial growth factor is related with the
natural course of breast cancer progression.
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The growth of solid tumours and their metastatic spread is angio-
genesis-dependent (Folkman, 1990, 1995). Angiogenesis that results
in tumour microvascularity is an acknowledged early requirement
for both tumour growth and dissemination (Ellis and Fidler,
1996). The change to the angiogenic phenotype may be due to
the over-expression of a number of endothelial growth factors,
such as vascular endothelial growth factor (VEGF) (Folkman,
1995). VEGF works as a principal mediator of normal and patho-
logical angiogenesis (Ferrara and Davis-Smyth, 1997) and is
secreted by a wide variety of cell types, including neutrophils,
platelets and tumour cells (Senger et al, 1993; Amoroso et al,
1997; Taichman et al, 1997; Verheul et al, 1997). Furthermore,
tumour associated stroma has also been shown to produce VEGF
(Fukumura et al, 1998). VEGF consists of several splice variants
yielding proteins of 121, 145, 165, 189, and 206 amino acids
(Houck et al, 1991; Veikkola et al, 2000). In tissue, VEGF165 is
the predominant isoform, and VEGF121 and VEGF165 are secreted
into the circulation (Neufeld et al, 1999). Furthermore, related
peptides have been described, i.e. VEGF-B, C, D and E (Neufeld
et al, 1999).
Many types of malignant human tumours have been shown to
produce VEGF. In previous studies the prognostic value of VEGF
in patients with different malignancies, e.g. malignancies of the
female tract (Abulaﬁa et al, 1999; Hazelton et al, 1999; Santin et
al, 1999; Tjalma et al, 2000; Boss et al, 2001), prostate (Bok et
al, 2001), colon (Cascinu et al, 2001), urinary bladder (Sato et
al, 1998; Crew et al, 1999), renal cell (Nicol et al, 1997) and thyr-
oid gland (Lennard et al, 2000) has been investigated.
The prognostic value of VEGF has also been evaluated in inva-
sive breast cancer in previous descriptive, retrospective studies
(Gasparini et al, 1997, 2001; Eppenberger et al, 1998; Linderholm
et al, 1998, 1999, 2000; Coradini et al, 2001). Two of these evalu-
ated VEGF in heterogeneous series of patients including both
node-negative and node-positive patients (Eppenberger et al,
1998; Linderholm et al, 2000). Five studies investigated the prog-
nostic value of VEGF only in node-negative patients (Gasparini
et al, 1997, 2001; Linderholm et al, 1998, 1999; Coradini et al,
2001). In three studies both treated and untreated patients were
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Linderholm et al (1999) focused on the node-negative patients that
were treated with radiotherapy. These previous studies have
concluded that the concentration of VEGF was of prognostic value
for relapse-free survival (RFS) (Gasparini et al, 1997, 2001; Eppen-
berger et al, 1998; Linderholm et al, 1999; Coradini et al, 2001)
and/or overall survival (OS) (Gasparini et al, 1997; Linderholm
et al, 1998, 1999, 2000) in different groups of patients.
In general, node-negative breast cancer patients who were trea-
ted with primary surgery have a relatively good prognosis,
however, about 30% of these patients will develop distant metasta-
sis within 10 years (Fisher et al, 1983; Saez et al, 1989). Prognostic
factors are needed to separate node-negative patients into low-risk
and high-risk groups in terms of the probability of recurrence and
to focus the treatment efforts on patients at high risk. Importantly,
to establish the prognostic value of a speciﬁc factor, the investi-
gated patients should not have received adjuvant systemic
therapy, because this may affect the relationship of the factor with
the natural course of the disease. Three of the above mentioned
studies included only patients who were not treated with adjuvant
systemic therapy, but they did not take all established prognostic
indicators into account in the performed analyses (Gasparini et
al, 1997, 2001; Coradini et al, 2001). The principal aim of this
study was to investigate the prognostic value of VEGF for RFS
and OS in patients with node-negative breast cancer, who were
not treated with adjuvant systemic therapy.
PATIENTS AND METHODS
Patients
A series of 1325 patients with operable breast cancer who under-
went resection of their primary tumour between January 1987
and December 1996 were selected by the availability of frozen
tissue in our tumour bank. This bank contains frozen tumour
tissue of patients with breast cancer from nine different hospitals
of the Comprehensive Cancer Center East in The Netherlands,
because in this hospital (University Medical Centre, Nijmegen)
the measurement of oestrogen receptor (ER) and progesterone
receptor (PgR) levels, by means of the ligand-binding assay, was
centrally done for these hospitals. The clinical data had to be retro-
spectively collected from these nine hospitals. To determine the
prognostic value of VEGF, patients were selected by having
node-negative breast cancer and by not having received adjuvant
systemic therapy (n=666). Thirty-two patients had evidence of
distant metastases at the time of diagnosis and eight had evidence
of disease within 1 month after primary surgery. These patients
were all excluded. Patients with previous diagnosis of carcinoma,
with the exception of basal cell skin cancer were also excluded
(n=20), as were patients with bilateral breast cancer (n=6) and
patients with only carcinoma in situ (n=26). In total, 574 patients
were considered assessable. Patients underwent a modiﬁed radical
mastectomy (n=345) or a breast conserving lumpectomy with axil-
lary lymph node dissection plus complementary radiotherapy
(n=225). There were also four patients who were treated by breast
conserving lumpectomy who did not receive additional radiother-
apy. Of the patients who underwent a modiﬁed radical
mastectomy, 64 received complementary radiotherapy. A resection
was considered complete when there were no tumour cells in the
inked border of the histological section. In case the margin was
not free, a re-resection or breast ablation was performed whenever
possible or additional radiotherapy was given. The median follow-
up time was 61 months (range 2–155 months). The median age
was 60 years (range 31–88 years). Further characteristics of
patients and tumours are listed in Table 1.
Of the 574 patients included in this study, 116 patients (20%)
showed evidence of relapse of disease during follow-up. The ﬁrst
relapses observed were: local recurrence in 25 patients, distant
metastasis in 77 patients and 14 patients had both. Forty-six
patients died due to breast cancer, while 24 patients died without
evidence of disease at last follow-up. There were 22 patients who
had a secondary primary tumour after the primary breast tumour.
These were not considered as failures.
Tumour tissue processing
After the surgery, a representative part of the tumour was selected
by the pathologist, frozen in liquid nitrogen and sent to this
department (Department of Chemical Endocrinology). The
primary breast cancer biopsies were stored in liquid nitrogen and
pulverised in the frozen state with a microdismembrator as recom-
mended by the European Organisation for Research and Treatment
of Cancer (EORTC) for analysing ER and PgR (EORTC Breast Co-
Operative Group, 1980). The tissue powders were suspended in
EORTC buffer, containing 20 mM K2HPO4/KH2PO4, 1.5 mM
K2EDTA, 3 mM sodium azide, 10 mM monothioglycerol, 10%
(v v
71) glycerol/water, pH 7.4 and centrifuged at 800 g for
20 min at 48C. The supernatants were collected and subjected to
further centrifugation for 1 h at 100000 g (48C). A part of the high
speed supernatants obtained (cytosols) were used for measurement
of ER and PgR levels by ligand-binding assay as previously
described (Koenders et al, 1977), the remaining cytosols were
stored at 7808C in liquid nitrogen. The protein concentrations
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Table 1 Categorical distributions of baseline characteristics in all patients
Total group of patients
a
Variable N=574 (%)
Age (years)
440 42 (7.3)
41–55 178 (31.0)
56–70 234 (40.8)
470 120 (20.9)
Menopausal status
Premenopausal 146 (25.4)
Postmenopausal 428 (74.6)
Surgery
Breast saving procedure 229 (39.9)
Mastectomy 345 (60.1)
Tumour type
Ductal 402 (70.0)
Lobular 69 (12.0)
Other 90 (15.7)
Tumour size
pT1 324 (56.4)
pT2 223 (38.9)
pT3+4 19 (3.3)
Histological grade
I 42 (7.3)
II 144 (25.1)
III 123 (21.4)
unknown 265 (46.2)
ER (fmol mg
71 protein)
510 138 (24.0)
510 407 (70.9)
PgR (fmol mg
71 protein)
510 160 (27.9)
510 385 (67.1)
VEGF (ng mg
71 protein)
50.53 286 (49.8)
50.53 288 (50.2)
aBecause of missing values, numbers do not always add up to 574 (100%).
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dard (Lowry et al, 1951).
Vascular endothelial growth factor assay
VEGF levels were determined in the primary breast tumour cyto-
sols with an ELISA developed by this department (Department of
Chemical Endocrinology) for the Receptor Biomarker Group
(RBG) of the EORTC. The assay measures VEGF165 and VEGF121,
the main isoforms of VEGF. The details of the assay, including
those of the speciﬁcity and performance, have been described else-
where (Span et al, 2000).
To increase the sensitivity of the VEGF assay, the horseradish
peroxidase labelled goat anti-rabbit detecting antibody was replaced
by a goat anti-rabbit alkaline phosphatase conjugate (A-3687,
Sigma Chemical Co, St. Louis, MO, USA). As substrate 4-methy-
lumbelliferyl phosphate (M-6491, Molecular Probes, Eugene, OR,
USA) in 10% diethanolamine was used. The reaction was stopped
with 1 M NaOH. Fluorescence was measured with a ﬂuorometric
plate reader (Fluoroskan, Lab Systems, Oy, Helsinki, Finland) using
355 nm excitation and 460 nm emission ﬁlters.
Data analysis
The median value of VEGF in this group of patients was used as
the cut off value in the statistical analyses when analysing VEGF
as a dichotomised variable.
To analyse interrelations between VEGF and various traditional
parameters, Spearman rank correlations were calculated for contin-
uous variables and the Kruskal–Wallis test for ordered variables.
Survival curves were generated using the method of Kaplan
and Meier (1958). For the univariate survival rate analysis, RFS
time (deﬁned as the time from surgery until the diagnosis of
recurrent disease) and OS time (deﬁned as the time between date
of surgery and death by any cause) were used as follow-up para-
meters. The survival curves only include the ﬁrst 96 months of
follow-up, because of the rapidly declining number of patients
thereafter. Patients with events after 96 months were censored
at 96 months
Cox univariate regression analysis was used in the analysis of the
associations between the different variables and RFS and OS, and
Cox multivariate regression analysis was used to evaluate the prog-
nostic value of VEGF in addition to traditional factors (Cox, 1972).
All computations were done with the SPSS statistical package
(release 10.0.5, November 1999). Two-sided P-values below 0.05
were considered to be statistically signiﬁcant.
RESULTS
Distribution of VEGF
Levels of VEGF protein were measured in 574 primary breast
tumour cytosols. In this series, a wide range of concentrations of
VEGF in cytosol, ranging from 0.00 to 48.03 ng mg
71 protein,
was observed. The median cytosolic VEGF level was 0.53 ng mg
71
protein. This value was used as cut off value to enable the analysis
of VEGF as a categorised variable (low, 50.53 ng mg
71 protein;
high, 50.53 ng mg
71 protein).
Relationships
The tumour levels of VEGF were not related to those of ER
(rs=70.065, P=0.132), or associated with histological grade
(P=0.082). Tumour VEGF levels were lower in patients with smal-
ler, compared with those with larger tumours (P=0.029). Tumours
from young patients had lower levels of VEGF than those of
patients who were older (P=0.042). VEGF levels were higher in
PgR-negative, compared with receptor-positive tumours
(rs=70.090, P=0.035).
Survival rate analyses
The 5-year probability of RFS was 84% for patients with low VEGF
levels and 75% for those with high VEGF levels. For OS, the 5-year
probability was 93% for patients with a low VEGF level and 86%
for those with a high level of VEGF.
Figure 1 show the results of the univariate RFS and OS rate
analyses for the total group of patients. After 8 years 79% of the
patients of whom the tumour had low VEGF levels
(50.53 ng mg
71 protein) were recurrence-free compared with
65% of those with high VEGF levels (P=0.005). When VEGF was
used as a continuous variable, also a signiﬁcant relationship of
higher VEGF levels with a poor RFS was observed (P=0.004). Simi-
larly, high VEGF levels were associated with a poor OS, both when
analysed as a continuous variable (P=0.004) and as a dichotomised
variable (P=0.005). At 8 years, 88% of the patients were alive in the
group of patients with low VEGF levels compared with 78% in
patients with high VEGF levels (Figure 1).
Cox analysis
In the Cox univariate regression analysis, young age, larger tumour
size, and negative ER and PgR status were signiﬁcantly associated
with a poor RFS and OS (Table 2 and 3). In contrast, histological
grade showed neither a signiﬁcant association with RFS nor with
OS. Since VEGF was shown to be of prognostic value in univariate
analysis, Cox multivariate analysis was performed to evaluate
whether it might signiﬁcantly add to the contribution of the tradi-
tional prognostic factors.
In the ﬁnal multivariate model, VEGF did still contribute to the
prognostic information already provided by the traditional prog-
nostic factors in the analysis for both RFS and OS (Table 2, RFS:
HR=1.56, P=0.029; Table 3, OS: HR=1.75, P=0.045). Together with
VEGF, age and PgR were signiﬁcantly associated with both RFS
and OS, while ER and histological grade were not. Tumour size
was only signiﬁcantly associated with RFS.
DISCUSSION
In this retrospective study, the prognostic value of VEGF was eval-
uated in 574 node-negative patients with primary breast cancer.
None of these patients were treated with adjuvant systemic therapy,
thus enabling the study of VEGF in relation to the natural course
of the disease. VEGF levels were found to be positively associated
with tumour size and negatively associated with ER and PgR status.
A high level of VEGF (50.53 ng mg
71 protein) was shown to
independently predict a short RFS and OS in patients with node-
negative breast cancer, in addition to age, tumour size and PgR.
Of note, these results in fact support the conclusion reported by
other investigators, i.e. that VEGF is indeed of prognostic signiﬁ-
cance in breast cancer (Gasparini et al, 1997, 2001; Eppenberger
et al, 1998; Linderholm et al, 1998, 1999, 2000; Coradini et al,
2001). Three of the previous studies investigated the prognostic
value of VEGF in node-negative patients who were not treated with
adjuvant systemic therapy, which were similar to the current study
(Gasparini et al, 1997, 2001; Coradini et al, 2001). Gasparini et al
(1997) reported that VEGF was an independent prognostic factor
of RFS and OS in multivariate analyses in a smaller group of
node-negative patients with primary breast cancer (n=260), who
were not treated with adjuvant systemic therapy. Unfortunately,
they did not take age and histological grade into account in the
multivariate analysis, although these are established prognostic
indicators. In another study of Gasparini et al (2001) on the prog-
nostic value of thrombospondins-1 and -2 and their correlation
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British Journal of Cancer (2002) 87(7), 772–778 ã 2002 Cancer Research UKwith VEGF and thymidine phosphorylase, VEGF was statistically
signiﬁcant for RFS in 168 node-negative patients, who were not
treated with adjuvant systemic therapy, but again they did not take
all established prognostic factors into account in the multivariate
analysis, e.g. age, histological grade, ER and PgR. In a study of
Coradini et al (2001) on the contribution of VEGF to the Notting-
ham prognostic index, VEGF was of borderline signiﬁcance for RFS
in 226 node-negative patients who were not treated with adjuvant
systemic therapy.
Eppenberger et al (1998) showed that VEGF was prognostically
signiﬁcant for poor RFS in 305 node-negative and node-positive
breast cancer patients. However, the investigators also included
patients who received adjuvant systemic therapy, which makes it
more difﬁcult to draw conclusions about the true prognostic
impact of VEGF. In the study of Linderholm et al (1998), VEGF
was also statistically signiﬁcantly associated with OS in the multi-
variate analysis in 525 node-negative patients, but again patients
who had received adjuvant systemic therapy were included. More-
over, these authors only investigated the association with OS and
not with RFS. In another study Linderholm et al (1999) reported
that VEGF was of borderline signiﬁcance for OS in the multivariate
analysis in a small group of node-negative patients who were trea-
ted with radiotherapy. Linderholm et al (2000) investigated the
prognostic value of p53 and VEGF in node-negative breast cancer
patients. In this study VEGF was also statistically signiﬁcantly asso-
ciated with OS but not with RFS in the multivariate analysis
(n=485), but again patients who had received adjuvant systemic
therapy were included.
In the above mentioned studies, a clear distinction between the
prognostic vs predictive value of a factor was not always made. In
an earlier study by Foekens et al (2001) on the predictive value of
VEGF in breast cancer patients with advanced disease, it was
shown that a high VEGF level predicts a poor efﬁcacy of both
tamoxifen and chemotherapy in advanced breast cancer. It is
important to stress, that to determine the prognostic value of a
marker, patients who did not receive adjuvant systemic treatment
should ideally be studied. In addition, the primary endpoint of
such analyses should be RFS and not OS, as for the latter, the
impact of systemic adjuvant treatment after relapse is also taken
into account.
In the current study the histological grade is missing for 46% of
the patients. In previous studies 20–25% of the patients had a
missing value for this variable (Eppenberger et al, 1998; Linder-
holm et al, 1998, 1999, 2000) or it was not included in the
analyses (Gasparini et al, 1997, 2001). Coradini et al (2001)
included the Nottingham prognostic index, which is based on
morphopathologic features, i.e. lymph node status, tumour size
and histological grade. Also, in the current study, the histological
grade was included in the univariate Cox analyses for those
patients for which it was available, but probably due to a substan-
tial number of missing data, it was not a signiﬁcant predictor of
relapse.
It was not the intention of this study to ﬁnd an optimal cut off
value for VEGF in cytosols of tumour tissue of breast cancer
patients and it was decided to use the median level in the group
of patients. From a biological point of view, such an arbitrary
assignment might be inappropriate. Alternatively, every conceivable
cut off value might be sequentially examined to maximise the
separation of the RFS and OS curves. However, if the total data
set would have been used to ﬁnd the optimal cut off value, one still
needs an independent data set to validate this cut off value
(McGuire, 1991). Further studies are needed to determine the opti-
mal cut off value for clinical use. Two of the before mentioned
studies also used the median value as the cut off value (Linderholm
et al, 1998, 1999). Eppenberger et al (1998) used the ﬁrst quartile
value to dichotomise the sample set. On the other hand, Gasparini
et al (1997, 2001) used a spline function and Linderholm et al
(2000) identiﬁed the cut off value with the smallest P-value and
the highest relative risk for death. Coradini et al (2001) did not
dichotomise the sample set, they used the 25th, 50th and 75th
percentiles for VEGF.
Several studies documented that in invasive breast cancer the
level of VEGF is highly associated with the degree of angiogenesis,
assessed by microvessel count (Toi et al, 1995b; Anan et al, 1996;
Obermair et al, 1997). Previous investigators have studied the
prognostic value of the degree of vascularisation of the tumour
by measuring intratumoural microvessel density (MVD). Some of
them demonstrated that MVD is of prognostic value for patients
with node-negative primary breast cancer (Gasparini et al, 1994;
Obermair et al, 1995; Toi et al, 1995a), but not all (Ellis and Fidler,
1995).
It is of clinical interest to establish new prognostic factors that,
in addition to the factors used up till now, could distinguish
subgroups of patients with node-negative invasive breast cancer
with a high risk for relapse that might beneﬁt from adjuvant
systemic therapy (National Institutes of Health Consensus Devel-
opment Panel, 1992; Henderson, 1992; Osborne, 1992; Gasparini
et al, 1993). Knowledge of these factors is also important for stra-
tiﬁcation in phase III trials and to explain different outcomes
between trials with a comparable design.
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B
Figure 1 RFS (A) and OS (B) as a function of VEGF values. For each
data set original VEGF values in the primary breast tumours were divided
into two groups: 5 or 50.53 ng mg
71 protein. Events indicate the num-
ber of patients at risk in each group. Patients at risk at 0, 24, 48, 72 and 96
months after primary surgery are indicated.
Prognostic value of VEGF in node-negative breast cancer
P Manders et al
775
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(7), 772–778In conclusion, our data suggest that VEGF is an independent prog-
nostic factor for RFS and OS in patients with node-negative breast
cancer. The present ﬁndings indicate that VEGF represents a biologic
marker of breast tumour angiogenesis. Further studies are warranted
to investigate whether patients with high VEGF levels are more likely
to gain beneﬁt from (antiangiogenic) systemic adjuvant therapy.
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Table 2 Cox univariate and multivariate analysis of relapse-free survival
Univariate analysis Multivariate analysis
a
Factor P-value HR
b (95% CI)
b P-value HR
b (95% CI)
b
Age (years) 50.001 50.001
440 1 1
41–55 0.23 (0.13–0.41) 0.26 (0.14–0.47)
56–70 0.30 (0.18–0.52) 0.32 (0.18–0.55)
470 0.29 (0.16–0.54) 0.31 (0.16–0.58)
Histological grade 0.060
I1
II 2.32 (0.70–7.69)
III 3.51 (1.07–11.49)
Tumour size 0.003 0.018
pT1 1 1
pT2 1.65 (1.12–2.42) 1.34 (0.89–2.03)
pT3+4 3.03 (1.38–6.68) 3.01 (1.38–6.95)
ER status
c 0.003
Negative 1
Positive 0.56 (0.38–0.82)
PgR status
c 50.001 50.001
Negative 1 1
Positive 0.39 (0.27–0.56) 0.48 (0.32–0.71)
VEGF levels
d 0.005 0.029
Low 1 1
High 1.73 (1.18–2.52) 1.56 (1.05–2.33)
aThe ﬁnal multivariate model with all the factors known included 538 patients.
bHazard ratio (95%
conﬁdence interval) of univariate and multivariate analysis.
cCut off points used for ER and PgR,
10 fmol mg
71 protein.
dLow: 50.53 ng mg
71 protein; high: 50.53 ng mg
71 protein.
Table 3 Cox univariate and multivariate analysis of overall survival
Univariate analysis Multivariate analysis
a
Factor P-value HR
b (95% CI)
b P-value HR
b (95% CI)
b
Age (years) 50.001 50.001
440 1 1
41–55 0.13 (0.05–0.33) 0.15 (0.06–0.40)
56–70 0.38 (0.19–0.76) 0.37 (0.18–0.76)
470 0.58 (0.27–1.23) 0.54 (0.30–1.38)
Histological grade 0.291
I1
II 2.06 (0.47–9.98)
III 2.86 (0.67–12.31)
Tumour size 0.009
pT1 1
pT2 2.07 (1.22–3.54)
pT3+4 3.25 (1.13–9.37)
ER status
c 0.004
Negative 1
Positive 0.47 (0.28–0.79)
PgR status
c 50.001 50.001
Negative 1 1
Positive 0.31 (0.19–0.51) 0.34 (0.20–0.57)
VEGF levels
d 0.005 0.045
Low 1 1
High 2.12 (1.25–3.59) 1.75 (1.01–3.02)
aThe ﬁnal multivariate model with all the factors known included 545 patients.
bHazard ratio (95%
conﬁdence interval) of univariate and multivariate analysis.
cCut off points used for ER and PgR,
10 fmol mg
71 protein.
dLow: 50.53 ng mg
71 protein; high: 50.53 ng mg
71 protein.
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